知识中心

Are you studying viruses, toxins, infectious agents, pathogens or infectious organisms which pose a moderate hazard to humans or the environment? Are you using differential scanning calorimetry (DSC) for characterization? If you answered YES, you likely have your instrument in a Biosafety Level 2 (BSL-2) lab. This means your DSC needs to be safely decontaminated after use.

The Zetasizer ZS Xplorer software is a powerful tool for size and zeta potential measurements. There are several ways for you to customize your workspace and tables in the software with an abundance of parameters to choose from. Understanding the meaning behind all the terms enables you to appreciate both the hardware and software’s versatility. Furthermore, having a glossary of these terms provides valuable insight.

Whilst dynamic light scattering (DLS) is a ubiquitous tool for the characterization of nanomaterials, there may be cases where we want to also know about larger material that might also be present within the sample. Here we will introduce a new analysis model to help characterize particles at sizes not typically measurable via DLS with some examples of the benefits and limitations of this new feature.

IntroductionThis technical note discusses interpretation of data and results obtained from zeta potential measurements in the ZS Xplorer software for the Zetasizer Advance series of instruments and highlights various parameters and charts that can be used to assess data and result quality. Recommended ParametersTable 1 shows a list of recommended parameters that are available in ZS Xplorer software which can be used to aid interpretation of the data and results obtained. Table 1: Recommended parameters for aiding data and result interpretation.Parameter NameDescription Zeta potentialThe mean zeta potential value in millivolts (mV) Zeta deviationThe standard deviation of the zeta potential distribution in millivolts (mV) ConductivityThe conductivity of the sample determined from the measurement in milli Siemens per centimeter (mS/cm) (Zeta Data) Mean count rateThe mean count from the measurement in kilo counts per second (kcps) at the attenuator selected for the measurement AttenuatorThe attenuator position used during the measurement (Zeta Data) Derived Mean Count RateThe normalized count rate (in kcps) obtained from the mean count rate and the attenuator selected for the measurement Reference beam count rateThe count rate of the reference beam (in kcps). This is set during instrument manufacture to be 2,600 ± 200 kcps Quality factorA signal to noise-based parameter derived from a phase analysis during the Fast Field Reversal (FFR) stage of the measurement SFR spectral quality factorA signal to noise-based parameter that is derived from the frequency analysis during the Slow Field Reversal (SFR)stage of the measurement Number of zeta runsThe number of sub runs used in the measurement Please login or register for free to read more.

The Zetasizer Advance range is the new family of versatile light scattering instruments for measuring the particle size, zeta potential and molecular weight of dispersed nanomaterials via Dynamic, Electrophoretic and Static Light Scattering (DLS, ELS and SLS, respectively). This new range of instruments has been developed with the market-leading Zetasizer Nano range as its foundation. While there are many similarities between the Zetasizer Nano and Zetasizer Advance systems, this document aims to help you understand the differences and ensure that you are confident in transferring methods between instruments in the two ranges. The following topics will be covered: Hardware differencesCell compatibilitySample analysis Setting up methodsInterpreting resultsConsiderations for sample preparation procedures Please login or register for free to read more

Operators of the Archimedes Particle Metrology System are frequent users of the fluidics feature known as the “Sneeze”. Most commonly it is activated as part of maintaining a clog-free microfluidic system. What exactly is happening during a sneeze is not well understood. Furthermore, the graphical display occurring during a sneeze can be misleading. In this technical note, we explain the mechanics of the Sneeze. We present a variety of scenarios and their resulting graphical output to illustrate and explain what is happening within the sensor and microfluidic system.

Antibody-drug conjugates (ADCs) are attracting a significant amount of attention as they have the potential to revolutionize cancer treatment. Chemical ligation of cytotoxic agents to monoclonal antibodies allows the selective delivery of cytotoxins to tumor cells thereby potentially mitigating some of the damaging side-effects of cancer chemotherapy. There are currently a number of FDA-approved ADCs and numerous others at varying stages of development. Concept Life Sciences has expertise in all aspects of ADC synthesis and characterization to help expedite your ADC projects from discovery to the clinic.

Concept Life Sciences offer a range of services important to any PROTAC® development programme. Our Medicinal, Synthetic and Computational Chemists, ADME Scientists and Biologists work closely together, allowing a flow of data and ideas between departments to help you accelerate your design-make-test cycle time.

Nucleosides and Nucleotides receive extensive synthetic attention due to their numerous uses in therapeutic and biotechnology applications. Examples include Sofosbuvir1, an important antiviral medication for the treatment of the hepatitis C virus (HCV) which works as a selective inhibitor of HCV NS5B polymerase with a high barrier to viral resistance, and more recently Remdesivir2 for its potential use in the treatment of Covid-19. Concept Life Sciences has unrivaled expertise in the synthesis of nucleosides and nucleosides from route development to synthesis of mg to kg scale.

Over the last twenty years fragment-based drug design (FBDD) has emerged as one of the most prominent strategies used to identify innovative drug discovery Hits. FBDD presumes drug molecules are made of a combination of small fragments, each contributing to the a nity of the drug for its biological target. Unlike HTS, which aims to identify moderate to high a nity Hits the size of a typical drug molecule, fragment screening scouts for small molecule Hits with weaker but leaner a nity to their biological target. The FDBB strategy had led to many drug discovery successes including 4 approved drugs and another 40 under clinical investigation. At Concept Life Sciences, our FBDD service is designed to enhance success rate and speed of delivery.